home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Antibiotic alternatives for the new millennium

 
  March 12, 2014  
     
 


EuroSciCon, Cineworld: The O2 Peninsula Square London London SE10 0DX United Kingdom
Wednesday, 05 November 2014 09:30 - Friday, 07 November 2014 17:00


The inexorable rise in the incidence of antibiotic resistance in bacterial pathogens, coupled with the disappointingly low rate of emergence of new,clinically useful antibiotics, has refocused attention on finding alternatives to antibiotic treatments. This event will discuss the potential utility of phages, probiotics, antimicrobial peptides, herbal medicines and immune modulation for treating human and animal disease. This event has CPD accreditation.

Who Should Attend 
From researchers trying to find alternatives to therapies to pharmacists delivering treatments: any one with an interest in antibiotic alternatives would find this event of value.

This event has an open oral and poster session.  
Abstract can be submitted on any subject related to antibiotic alternatives

The deadline for abstract submissions for oral presentation is August 10th 2014
Abstracts for poster presentation only can be submitted up to two weeks before the eventYou can download the instructions for authors at 

www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf

 
 
 
 
Keywords:  Infection, Bacteriophage, Resistance,Toxin ,Purification Monolith,Yield ,Scaleable, cGMP, clinical trials, regulation, FDA, EMA, therapeutic use, lung, infection, Campylobacter, phage therapy, poultry, biofilms, Clostridium difficile, genomes, diagnostic, therapeutic, Metagenomics, ecology, microbial functioning,  Genomics, Metabolism, Clostridium difficile, Pseudomonas aeruginosa, gastrointestine, probiotic, herbal, phage nanobiotechnology, antibiotic, antimicrobial peptides, Probiotics, adjunctive therapy, Bacillus probiotic, antagonistic activity, antibiotic-resistant pathogens, Antimicrobial peptides, flaviviruses, alphaviruses, bacteria, antibiotic alternatives, Antimicrobial peptides, antibiotic resistance, staphylococcal biofilms, Probiotics,Immunomodulators,Antiinflammatory, Antiarthritis,Lactobacilli, Androstenes; Steroids; Infection; viral and bacterial :Immune regulation, antibiotics, mult-drug resistance, octatpeptins, polymyxins, Maggot wound therapy, diabetic foot ulcer, chronic wound, wouund healing, antibiotic time, Androstenes; Steroids; Infection; viral and bacterial :Immune regulation, Quorum senser, device associate infection, anti-microbial agents, auto-inducers, Tuberculosis, host, signalling, phagosome, macrophage, Antibodies, peptides, antibiotics, immunomodulators,Innate Immunity, Macrophages, Immunoregulation, Nitric Oxid, Staphylococcus aureus, phage therapy,  antibiotic  resistance, phage-bacteria interactions 
 
 
Organized by: Euroscicon
Invited Speakers: Talks Include:

Novel Host Therapeutic Targets regulating M.tuberculosis infection
Mr Cornelis Korbee, PhD Student, Leiden University Medical Center, The Netherlands

Pro- & Synbiotics - an alternative to antibiotics?
                                       
Professor Stig Bengmark, Honorary Visiting Professor, Division of Surgery & Interventional Science, University             College London, UK

HBD3 regulates matrix metalloproteinase production in human myeloid dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B (HagB)
Professor Kim A. Brogden, Director, Dows Institute for Dental Research,  

The University of Iowa, USA

 

Quorum sensing inhibitors as an alternate to conventional antibiotics Dr. Pragasam Viswanathan, Associate Professor, VIT University, India 

Serendipity, bees, honey and wounds.
Dr Matthew Dryden, Royal Hampshire County Hospital, UK

Antibiotic versus maggot therapy in diabetic foot ulcer
Professor Chumpon Wilasrusmee, Department of Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand

Development of bacteriocins for therapy of infections caused by Gram positive and negative MDR pathogens
Dr Mathew Upton, School  of Biomedical & Healthcare Sciences, Plymouth University, Plymouth, UK

Bacteriophages for antistaphylococcal therapies – natural repertoire and limitations of choice
Dr Hab  Algorzata, Institute of Biochemistry and Biopysics of the Polish Academy of Sciences, Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Poland

Host-Defense Peptides to New Antimicrobial Agents
Dr Paul R. Hansen, University of Copenhagen, Denmark

Anti-microbial cationic peptides as a strategy for innovation in global health therapeutics for human infectious diseases
Dr Hussin Rothan, Researcher, Faculty of Medicine, University of Malaya, Kuala Lumpur , Malaysia

Antibodies as a limitless source of peptides with innate microbicidal and immunomodulatory activity (ultrabodies)
Professor Luciano Polonelli, Full University Professor, University of Parma, Italy

Octapeptins revisited 
Dr Tony Velkov, Monash Institute of Pharmaceutical Sciences, Victoria, Australia

Using molecular simulations to understand the dual action of peptides in antimicrobial activity and innate immune modulation
Dr Peter J Bond, Principal Investigator Bioinformatics Institute, A*STAR, Singapore.  Adjunct Assist. Professor, Dept. Biological Sciences, National University of Singapore, Singapore

Preclinical development of a novel synthetic antimicrobial peptide for lung infections and sepsis
Dr Alessandro Pini, Dept. of Medical Biotechnology, University of Siena, SetLance srl Toscana Life Sciences, Italy

Enhancing Host Resistance against Lethal Infections
Professor Roger M. Loria, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA

Echinoderms as source of novel antimicrobial peptides to contrast human pathogens

Dr Domenico Schillaci, Lecturer, University of Palermo, Palermo, Italy

War against Microbes: are Antibiotics the only Weapons?
Dr. Jayanta Haldar, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India

Antibiotics in Modulation of M1 and M2 Macrophage Responses
Dr Charles Mills, BioMedical Consultants, USA

Probiotic bacteria against multiresistant pathogens

Professor Iryna SorokulovaAuburn University, Auburn, AL, USA

Antibiotic therapy corroborated by selected immunomodulating beta blockers                              
Dr. Karin Peuschel, CNP, Switzerland

Clinical Application of Probiotics in Antibiotic Therapy: the Current and Future Use

Dr Thomas A. Tompkins, Research Director, Lallemand Health Solutions Inc, Montreal, Canada
 
Deadline for Abstracts: August 10th 2014
 
Registration: Click here to register
E-mail: enquiries@euroscicon.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.